缺血修饰白蛋白在缺血性脑卒中患者中的临床应用

Clinical Application of Ischemia-modified Albumin in Diagnosis of Ischemic Stroke

目的探讨缺血修饰白蛋白(IMA)在缺血性脑卒中(IS)发病早期的临床价值。方法本研究为临床实验研究。选取2011年1月至12月本院确诊的缺血性脑卒中患者86例,按照发病时间分为5组,3h、6h、12h、24h和48h组,采用白蛋白钴结合试验检测IMA的数值,观察在各个时间段数值分布,采用单因素方差分析组间区别。结果 20名健康对照者IMA浓度为75.0±8.6U/mL。在IS发生后3h,患者体内的IMA即显著增高,为99.1±11.7U/mL;在发病48h后,血清IMA浓度显著降低至87.3±26.5U/mL。3h、12h和24h组脑卒中患者与健康对照组间IMA水平有统计学差异,P值分别为0.004、0.049、0.002。结论 IMA是一个IS早期诊断实验室指标。

Objective To explore clinical values of ischemia modified albumin（IMA） in early diagnosis of ischemic stroke（IS）.Methods 86 cases of IS patients were divided into 5 groups according to the time of IS onset 3h,6h,12h,24h and 48h group.The serum IMA levels in IS patients and 20 health controls were tested by using albumin cobalt binding test.Results The concentration of IMA in 20 healthy controls was 75±8.6U/ml.IS onset 3h later,IMA increased significantly to 99.1±11.7 U/mL.Whiles 48h later,the serum IMA concentration was reduced to 87.3±26.5 U/mL.The IMA concentration of IS patients in group of 3 h,12 h and 24 h were significant higher than that of healthy controls,the P values were 0.004,0.049 and 0.002 respectively.Conclusion The ischemia modified albumin is useful biochemical marker for early diagnosis of ischemic stroke.